Guardant Health (GH) stock in plain English
Every company we rate gets Strong Buy, Buy, Buy with Caution, Hold or Sell. Members see the rating for this company and the five scores behind it.
Change shown by the quote provider. Data may be delayed.
What does Guardant Health (GH) do?
Guardant Health Inc (GH) is a U.S.-listed company in Healthcare (Diagnostics & Research). What it does: Sells blood-based cancer tests to oncologists, researchers, and pharmaceutical companies for clinical profiling and recurrence monitoring. Processes blood samples to detect cancer DNA, helping doctors select therapies and screen for recurrence without. It is worth $19.70B on the market and sold $1.28B over the last year.
- Market cap
- $19.70B
- P/E ratio
- None (reported a loss)
- Annual sales
- $1.28B
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Brief updated
- Nov 18, 2026
Brands and businesses behind GH
- Guardant360: A blood test providing comprehensive genomic profiling for advanced cancer patients to guide targeted therapy decisions.
- Shield: An FDA-approved blood test that screens average-risk adults for colorectal cancer during routine health checkups.
- Guardant Reveal: A blood test detecting minimal residual disease to monitor early-stage cancer recurrence risks after surgery.
GH’s flags, in plain English
Each flag is a number from Guardant Health’s reports to the SEC or from market data, with the reason it matters. This brief was updated on Nov 18, 2026.
Still Climbing
Sales up 27.9% a year over 5 years. Sales are higher than a year ago. Growth does not guarantee profit, so look at the margins too.
Stupid Cash
Can pay this year's bills 3.6 times over. Cash in the bank covers a long stretch of running costs. The company can fund itself without borrowing or selling new shares.
Wide Gross Margin
Gross margin of 65.2% after the cost of making its products. There is a large gap between what its products cost to make and what they sell for, and that gap pays for everything else.
Burning Cash
Losing money, profit margin of -37.9%. The business spends more cash than it brings in. It has to cover the gap with cash on hand, new loans or new shares.
Questions about GH
How big is Guardant Health?
Guardant Health’s market cap is $19.70B: what all of its shares are worth together at today’s price. Its annual sales (revenue) are $1.28B: what customers paid the company over the last year, before any costs.
What is GH’s P/E ratio?
GH has no P/E ratio right now. The company reported a loss, so there is no yearly profit to price.
What could go wrong with GH?
The business remains unprofitable and continues to spend substantial cash on clinical studies and commercial expansion. That is one risk on Guardant Health’s card. Its first risk flag is Burning Cash, explained above. A flag reads what the company reported. It does not predict the price.
Where do these numbers come from?
From Guardant Health’s own reports to the SEC (annual and quarterly) and from market data. Every company runs through the same scoring formula, and a reviewer spot-checks cards against the source data. GH’s filings on SEC.gov. The Margin Monkey is research, not advice.
